The present invention relates to a method for producing hydroxyapatite-bioglass macroporous material, to said materials, and to medical devices thereof.

The method comprises a step of preparation of an aqueous suspension of hydroxyapatite and bioglass with a porogenic agent, and subsequent sintering to achieve a macroporous biomaterial.

The macroporous structure of these materials enhances blood vessels and bone cells migration, allowing bone growth through the interior of the bone substitute, thereby increasing the rate of formation of new bone at the site of implantation. Therefore, these materials are advantageously used to produce medical devices, such as bone grafts that resemble the mineral phase of natural bone showing improved mechanical strength and osteoconductivity.

The biomaterials of the present invention are applicable in the medical area, in particular in bone regeneration and reparation techniques as bone grafts.

A glass, glass-ceramic, or ceramic bead is described, with an internal porous scaffold microstructure that is surrounded by an amorphous shield. The shield serves to protect the internal porous microstructure of the shield while increasing the overall strength of the porous microstructure and improve the flowability of the beads either by themselves or in devices such as biologically degradable putty that would be used in bone or soft tissue augmentation or regeneration. The open porosity present inside the bead will allow for enhanced degradability in-vivo as compared to solid particles or spheres and also promote the growth of tissues including but not limited to all types of bone, soft tissue, blood vessels, and nerves.

Compositions and methods for glass composites suitable for tissue augmentation, biomedical, and cosmetic applications are provided. The glass microsphere component of the composites are biologically inert, non-reactive and act as a nearly permanent tissue filler. One embodiment provides a tissue augmentation composite containing an effective amount of solid glass microspheres, hollow glass microspheres, porous wall hollow glass microspheres, or combinations thereof with a suitable biocompatible matrix to serve as a bulking agent when injected into a patient. The compositions can be used for soft or hard tissue augmentation as well as delivery of cargos on demand.

A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 15-45% CaO, 30-70% SiO.sub.2, 0-25% Na.sub.2O, 0-17% P.sub.2O.sub.5, 0-10% MgO and 0-5% CaF.sub.2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

A borophosphate glass composition including B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO, and optionally a source additive selected from: Li.sub.2O, Na.sub.2O, K.sub.2O, Al.sub.2O.sub.3, ZnO, MgO, Fe.sub.2O.sub.3/FeO, CuO/Cu.sub.2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B.sub.2O.sub.3, P.sub.2O.sub.5, and CaO.

An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.

A gallium silica glass composition is described. The glass can be used in variety of biomedical applications

The disclosure provides a method of producing a mesoporous phosphate-based glass. The method comprises (a) contacting a phosphate with an alcohol and/or a glycol ether to create a reaction mixture; (b) contacting the reaction mixture with alkali metal cations and/or alkaline earth metal cations; (c) contacting the alcohol, the glycol ether or the reaction mixture with a surfactant, wherein the surfactant is configured to provide channel-like pores in the resultant mesoporous phosphate-based glass; (d) allowing the reaction mixture to gel; and (e) calcinating the gel to obtain the mesoporous phosphate-based glass.

A vitreous composition according to Table (I) is described. Continuous vitreous fibers are obtained by downdrawing said molten composition, with a length ranging from millimeters to kilometers and diameters ranging from 2 μm to 3 mm. The fibers are covered with collagen and form vitreous fabrics. The fabrics form articles with a variety of medical uses.

Methods for processing and or removing organic residuals and or impurities from a solgel-derived bioactive glass-ceramic and compositions comprising solgel-derived bioactive glass-ceramics processed using these methods, are described.